Roivant Sciences Ltd. (ROIV)
41.43
+6.50
(+18.61%)
USD |
NASDAQ |
Sep 08, 15:59
41.30
-0.13
(-0.31%)
After-Hours: 20:00
Roivant Sciences Shareholders Equity (Quarterly) : 4.231B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.231B |
| March 31, 2026 | 4.527B |
| December 31, 2025 | 4.269B |
| September 30, 2025 | 4.362B |
| June 30, 2025 | 4.346B |
| March 31, 2025 | 4.688B |
| December 31, 2024 | 5.189B |
| September 30, 2024 | 5.153B |
| June 30, 2024 | 5.435B |
| March 31, 2024 | 5.969B |
| December 31, 2023 | 6.090B |
| September 30, 2023 | 948.53M |
| June 30, 2023 | 910.73M |
| Date | Value |
|---|---|
| March 31, 2023 | 1.158B |
| December 31, 2022 | 955.52M |
| September 30, 2022 | 1.161B |
| June 30, 2022 | 1.384B |
| March 31, 2022 | 1.657B |
| December 31, 2021 | 1.866B |
| September 30, 2021 | 2.038B |
| June 30, 2021 | 1.823B |
| March 31, 2021 | 1.898B |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | 2.032B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Oxford Biomedica Plc | -- |
| Bicycle Therapeutics Plc | 510.26M |
| Arbutus Biopharma Corp. | 258.73M |
| Moderna, Inc. | 6.761B |
| Adaptimmune Therapeutics Plc | -70.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 5.306B |
| Total Liabilities (Quarterly) | 384.62M |
| Debt to Equity Ratio | 0.0253 |
| Current Ratio | 16.72 |
| Net Debt Paydown Yield | -0.01% |